AT-31 BIO Inc. aims to discover new drug candidates and successfully develop innovate new drugs which contribute to a healthy and happy society by overcoming diseases caused by inappropriate operations of the immune system. Currently, we are conducting empirical studies using cutting-edge research techniques on the immunosuppressive efficacy of monosaccharide which can be mass-produceed from our own enzymatic complete hydrolysis of agarose. We are also conducting preclinical studies using animal disease models to explore and establish indications for our potential drug candidates. Through these research approaches, We hope to open new horizons in the prevention and treatment of autoimmune diseases, transplant rejection, and hypersensitivity immune diseases, which are representative of unmet medical needs.
What is your business/industry sector?
Partnership
Areas of Interest for international collaboration
Seeking to collaborate with pharmaceutical companies and researchers being committed to manufacture drugs for treatment of autoimmune diseases (Sjögren’s syndrome dry eye, IBD, AD, and MS) to develop new drugs containig GJK-012 as the active ingredient.
Partnership
Areas of Interest for international collaboration
Seeking to collaborate with pharmaceutical companies and researchers being committed to manufacture drugs for treatment of autoimmune diseases (Sjögren’s syndrome dry eye, IBD, AD, and MS) to develop new drugs containig GJK-012 as the active ingredient.